Abstract:
본 발명은 이온성 액체계 용액을 사용한 올레핀으로부터 아세틸렌류의 제거방법에 관한 것으로서, 더욱 상세하게는 구리 할라이드(CuX, X=할로겐원자)가 용해되어 있는 이온성 액체계 용액을 사용하여 올레핀에 미량으로 함유된 아세틸렌류를 효율적으로 제거하는 방법에 관한 것이다. 본 발명에서 사용하는 이온성 액체계 용액은 구리 할라이드(CuX)가 이온성 액체에 의해 안정화되어 존재하므로, 1가 구리이온(Cu + )이 2가 구리이온(Cu 2+ )으로 산화되는 현상이 방지되어, 아세틸렌 제거능이 높은 1가 구리이온(Cu + )의 성능이 장시간 유지될 뿐만 아니라 올레핀에 대한 아세틸렌계 화합물의 선택적 제거율이 크게 증가한다. 또한, 본 발명에서 사용하는 이온성 액체계 용액은 흡수액으로 뿐만 아니라 추출액으로 사용이 가능하여 기존의 슬러리 상태에서 추출제를 사용한 경우에 비해 훨씬 운전이 간편하고 장치비가 감소하는 장점이 있다. 아세틸렌류 제거, 올레핀, 이온성 액체, CuCl, CuBr, CuI
Abstract:
PURPOSE: A method for removing acetylenes from olefins is provided to effectively remove an acetylene-based compound from olefins using an ionic liquid-based solution, and to reduce solvent loss rate and device costs. CONSTITUTION: A method for removing acetylenes from olefins uses an ionic liquid-based solution. The ionic liquid-based solution comprises at least one or two kinds of ionic liquid selected from an imidazolium compound represented by chemical formula 1, and copper halide. In chemical formula 1, R^1 and R^2 show C1-6 alkyl group, or C1-6 alkoxy group; Y is halogen ion, phosphate ion[R^3OPH(O)O]^-, or phosphate ion[(R^3O)2P(O)O]^-; and R^3 C1-6 alkyl group.
Abstract:
PURPOSE: Cephalosporin derivatives, its pharmaceutically acceptable salts and a manufacturing process thereof are provided, which cephalosporin derivatives have improved anti-microbial activity, particularly, for methicillin-resistant Staphylococcus aureus(MRSA) strain, so that they can be useful for antibiotics. CONSTITUTION: The cephalosporin derivatives represented by formula (I), or pharmaceutically acceptable salts thereof are provided, wherein X, Y and Z are the same or different, and independently hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 halogenoalkyl, C1-6 alkoxy alkyl or C3-6 cycloalkyl; R1 is an isoxazol compound in which the 3-site is substituted with a compound of formula (A), wherein Q is a substituent useful for cephalosporin-based compound, and is selected from hydrogen, halogen, hydroxyl, mercapto, cyano, carboxy, carboxylic acid, ester, carbamoyloxy, carbamoyl, N,N-dimethylcarbamoyl, C1-4 alkyl, C1-4 alkyloxy, halogen substituted alkyl, aryl or hetero ring substituent; and R2 is hydrogen, an ester-forming group as an ester of carboxy group, salt-forming atom or carboxy-protecting group. The process for preparing the cephalosporin derivatives represented by formula (I), or pharmaceutically acceptable salts thereof comprises reacting an ilide compound of formula (VI) with an aldehyde compound of formula (VII) in the presence of base and organic solvent at -40 to 25 deg. C.
Abstract:
A composition comprising the extract, a fraction or an isolated compound of Thuja orientalis is provided to inhibit sorbitol accumulation and non-enzymatic saccharification causing neurological disorder and neurological damage by inhibiting aldose reductase, so that the composition is useful for prevention or treatment of diabetic complications. A composition for prevention or treatment of diabetic complications comprises the extract, a fraction or an isolated compound of Thuja orientalis such as quercitrin which is isolated by (1) extracting Thuja orientalis with water, C1-C4 lower alcohol or a mixture thereof, (2) fractionating the extract of Thuja orientalis with ethyl acetate, and (3) adding CH2Cl2-MeOH or hexane-ethylacetate into the fraction of Thuja orientalis, and is a pharmaceutical or health food composition.
Abstract:
A composition comprising an extract of Phyllostachys nigra MUNRO, a fraction thereof or a compound isolated from the fraction is provided to inhibit accumulation of sorbitol, a fundamental cause of nephropathy and neuropathy shown as diabetic complications, by inhibiting aldose reductase, thereby being used as a pharmaceutical composition or a health food for preventing diseases related to the diabetic complications. A method for isolating a compound from Phyllostachys nigra MUNRO comprises the steps of: (a) extracting the Phyllostachys nigra MUNRO with ethanol and filtering the extract; (b) concentrating and freeze-drying the filtrate to obtain an extract; (c) fractionating an ethylacetate layer from the extract using a separation funnel; and (d) subjecting the fraction to silica gel column chromatography using CH2Cl2-MeOH as a solvent to obtain orientin, luteolin 6-C-(6''-O-transcaffeoylglucoside), tricetin 3',4',5'-trimethyl ether 7-O-b-D-glucopyranoside, tricine, p-coumaric acid or cis-coumaric acid. A pharmaceutical composition for preventing or treating diabetic retinopathy, diabetic neuropathy or diabetic nephropathy comprises the obtained compound as an effective ingredient.
Abstract:
본 발명은 하기 화학식 (I)의 신규한 세팔로스포린계 화합물 및 약제학적으로 허용되는 염과 그의 제조 방법에 관한 것이다. 상기 화합물은 메티실린 내성 스타필로코쿠스 아우레우스(MRSA)를 포함하는 그람양성균에 대해 우수한 항균 작용을 나타내므로, 항생제로써 유용하게 사용될 수 있다. [화학식 (I)]
상기 식에서, X, Y 및 Z는 서로 같거나 다를 수 있으며, 각각 독립적으로 수소, 할로겐, C 1-6 알킬, C 1-6 알콕시, C 1-6 할로게노알킬, C 1-6 알콕시 알킬 또는 C 3-6 사이클로알킬을 나타내고; R 1 은 하기 화학식 (A)로 표시되는 3-위치가 치환된 이소옥사졸 화합물이며; [화학식 (A)]
(여기서, Q는 세팔로스포린계 화합물에 유용한 치환기로써, 수소, 할로겐, 히드록시, 메르캅토, 시아노, 카르복시, 카르복시산, 에스테르, 카르바모일옥시, 카르바모일, N,N-디메틸카르바모일, C 1-4 알킬, C 1-4 알킬옥시, 할로겐이 치환된 알킬, 아릴 또는 헤테로고리 치환체를 나타낸다.) R 2 는 수소, 카르복시기의 유도체로써 에스테르를 만드는 기, 염을 만드는 원자 또는 카르복시기의 보호기를 나타낸다. 세팔로스포린, 이소옥사졸, 메티실린 내성 스타필로코쿠스 아우레우스, 항균 활성